Lung cancer screening: the way forward

To take lung cancer screening into national programmes, we first have to answer the question whether low-dose computed tomography (LDCT) screening and treatment of early lesions will decrease lung cancer mortality compared with a control group, to accurately estimate the balance of benefits and harm...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 99; no. 4; pp. 557 - 562
Main Authors FIELD, J. K, DUFFY, S. W
Format Journal Article
LanguageEnglish
Published Basingstoke Nature Publishing Group 19.08.2008
Subjects
Biological and medical sciences
Cost-Benefit Analysis
Humans
Lung cancer
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - mortality
Lung Neoplasms - therapy
Mass Chest X-Ray
Medical sciences
Minireview
National Health Programs
Pneumology
Survival Rate
Tomography, X-Ray Computed
Tumors
Tumors of the respiratory system and mediastinum
United Kingdom
Lung disease
cost-effectiveness
screening
Radiodiagnosis
Respiratory disease
Lung cancer
risk modelling
Exploration
X ray
Malignant tumor
CT screening
Medical screening
Radiography
Cancerology
Health economy
Risk factor
Bronchus disease
chest X-ray
Cancer
Cost efficiency analysis
Online AccessGet full text

Cover

More Information
Summary:To take lung cancer screening into national programmes, we first have to answer the question whether low-dose computed tomography (LDCT) screening and treatment of early lesions will decrease lung cancer mortality compared with a control group, to accurately estimate the balance of benefits and harms, and to determine the cost-effectiveness of the intervention.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6604509